Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To demonstrate that in patients with resistant hypertension oral treatment with minocycline via inhibition of central immune cell activation and inflammation results in reduced central sympathetic outflow and concomitant lowering of BP.
This is a randomized, double-blind, placebo controlled, parallel group design study aiming to compare the effects of minocycline 100mg twice daily vs matched placebo for 12 weeks on ambulatory BP and the parameters of sympathetic and immune activation
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Minocycline Group | Active Comparator | Subjects will be randomized to receive Minocycline 100mg twice daily |
|
| Placebo Group | Placebo Comparator | Subjects will be randomized to receive placebo. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Minocycline | Drug | Participants will be randomly assigned to receive either Minocycline 100mg twice daily or Placebo. Comprehensive testing will be performed at baseline, and at the end of the 12 week intervention phase. |
| Measure | Description | Time Frame |
|---|---|---|
| The difference in the daytime systolic blood pressure between groups after respective treatment. | Office and ambulatory blood pressures | 12 weeks |
| Assessment of change in central and peripheral inflammation | FDG PET | 12 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Change in muscle sympathetic nerve activity | Muscle sympathetic nerve activity assessed by microneurography | 12 weeks |
| Change in central Blood Pressure | central Blood Pressure assessed by Sphygmocor XCEL |
Not provided
Inclusion Criteria:
Exclusion Criteria:• eGFR of <45 mL/min/1.73m2
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Revathy Carnagarin, MD | Contact | +61892240316 | revathy.carnagarin@uwa.edu.au | |
| Omar Azzam, MD | Contact | +61892242244 | omar.azzam@health.wa.gov.au |
| Name | Affiliation | Role |
|---|---|---|
| Markus Schlaich, MD | University of Western Australia and Royal Perth Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Royal Perth Hospital | Recruiting | Perth | Western Australia | 6000 | Australia |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 30129037 | Background | Carnagarin R, Matthews V, Zaldivia MTK, Peter K, Schlaich MP. The bidirectional interaction between the sympathetic nervous system and immune mechanisms in the pathogenesis of hypertension. Br J Pharmacol. 2019 Jun;176(12):1839-1852. doi: 10.1111/bph.14481. Epub 2018 Sep 25. | |
| 25963715 | Background | Santisteban MM, Ahmari N, Carvajal JM, Zingler MB, Qi Y, Kim S, Joseph J, Garcia-Pereira F, Johnson RD, Shenoy V, Raizada MK, Zubcevic J. Involvement of bone marrow cells and neuroinflammation in hypertension. Circ Res. 2015 Jul 3;117(2):178-91. doi: 10.1161/CIRCRESAHA.117.305853. Epub 2015 May 11. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D008911 | Minocycline |
| ID | Term |
|---|---|
| D013754 | Tetracyclines |
| D009279 | Naphthacenes |
| D011084 | Polycyclic Aromatic Hydrocarbons |
| D006841 | Hydrocarbons, Aromatic |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| 12 weeks |
| D006844 |
| Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D009930 | Organic Chemicals |
| D011083 | Polycyclic Compounds |